2019-05-009 - NANOJANUS - Bispecific Janus Antibody Au Nanoparticles Conjugates as Universal Platform for Precision Cancer Immunotherapy

NANOJANUS

2019-05-009

Novel nanoparticle-based approach, in which the selective attachment of tumor cells to antigen-specific cytotoxic cells by using bispecific polarized (JANUS) conjugated nanoparticles (NP) is presented. Selective binding is generated by decorating Au nanoparticles with both an antigen-specific to an immune cell binding moiety and another tumor cell binding moiety

There is currently no cure for HIV/AIDS infection, so patients are forced to take antiretroviral drugs for life. The main obstacle to eradication of the virus is the establishment of what are known as "reservoirs", i.e. groups of immune cells (mainly CD4+ T lymphocytes) which the virus infects and in which it integrates its genome, so that it remains there in an inactive/latent state, which means that these latent cells cannot be the target of the effect of the drugs or the action of the immune system. The consequence is that when a patient stops antiretroviral therapy, in a short period of time, the virus "rebounds" and produces a new viraemia. It should be noted that antiretroviral drugs involve strict regimens, as well as the deterioration of certain functions of the organism in the long term, not to mention the economic cost to the health system. For this reason, research in the field of HIV is focusing on the so-called "shock and kill" therapies, which consist of reactivating latently infected cells with drugs to signal the presence of the virus, in order to achieve the development of a powerful immune response or even, due to the cytopathogenic effect of the reactivated virus itself, to eliminate the infection. Solution proposed: the development of gold nanoparticles that, thanks to their surface, allow the simultaneous presence of several antibody units, on the one hand several specific antibodies against an HIV protein (specifically gp120), and on the other hand, several units of another antibody, but in this case directed to a receptor expressed by NKs cells (CD16: receptor of low affinity for the immunoglobulin G-containing portion). With our experiments we have been able to demonstrate that these Bi-AuNPs are able to increase the binding between the two mentioned cell types and promote the elimination of gp120-expressing cells.

0

0

0

Looking for a licensee. It was supposed to be licensed to AEGLE Biomedical but in the end they refuse the license because they wanted to focus on other projects, as CollyriuNP.

There is currently no cure for HIV/AIDS infection

Pharma companies focused on HIV, worldwide.

The technology consists of an immunotherapy for the treatment of the HIV virus. The technical basis of this therapy is based on the development of gold nanoparticles, which simultaneously conjugate two antibodies to direct NK (Natural Killer) cells towards HIV-infected cells, identify them and thus eliminate them. These gold nanoparticles present two antibodies with different specificities 1- Antibody A32, which recognizes HIV-infected cells through the gp120 protein. 2- 3G8 antibody, which activates the elimination of cells that have been recognized by A32 (antibody-dependent cell cytotoxic activity). All these characteristics have already been tested by the research group. To proceed with the validation of this immunotherapy, an assay is being developed to evaluate the effect of Bi-AuNPs in an ex vivo infected cervico-vaginal tissue model. The final technology is a nanoparticle with polarized antibodies.

BI-FUNCTIONALIZED NANOPARTICLES, PROCESS FOR ITS PREPARATION AND USES THEREOF • EP19382675.7 Data sol·licitud: 2/8/2019 • PCT/EP2020/071635 31-07-2020

We are looking for a licensee, the patent costs are now be payed by the research groups involved .

This technology is a platform that has tremendous applicative prospective in nanotechnology enabled immunotherapy for a broad range of malignancies and realistic clinical future implementation